US20050287228A1 - Method and composition for improving fertility health in female and male animals and humans - Google Patents

Method and composition for improving fertility health in female and male animals and humans Download PDF

Info

Publication number
US20050287228A1
US20050287228A1 US11/214,927 US21492705A US2005287228A1 US 20050287228 A1 US20050287228 A1 US 20050287228A1 US 21492705 A US21492705 A US 21492705A US 2005287228 A1 US2005287228 A1 US 2005287228A1
Authority
US
United States
Prior art keywords
supplement
arginine
fertility
method
green tea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/214,927
Inventor
Aileen Trant
Original Assignee
Trant Aileen S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/742,412 priority Critical patent/US6497885B2/en
Priority to US10/252,698 priority patent/US7045151B2/en
Application filed by Trant Aileen S filed Critical Trant Aileen S
Priority to US11/214,927 priority patent/US20050287228A1/en
Publication of US20050287228A1 publication Critical patent/US20050287228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/85Verbenaceae (Verbena family)

Abstract

In a new pharmaceutical combination, the herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.

Description

    BACKGROUND OF THE INVENTION
  • Because of delayed child bearing, unhealthy diets and use of tobacco, caffeine, alcohol, drugs and environmental contaminants, difficulties in conceiving have been experienced.
  • Needs exist for pharmaceutical compounds that improve fertility in both women and men.
  • SUMMARY OF THE INVENTION
  • This invention provides combinations of bioeffecting compounds for promoting fertility in men and women. The combinations include nutritional components that benefit fertility health. All the components have been studied separately, to determine their individual efficacy. The invention provides the first products to put these components together synergistically in women's and men's formulations.
  • As many as 15% of couples in the U.S. have difficulty conceiving a child. In about one third of these cases, it is the man that is infertile; in another third, the female has fertility issues. The remaining is due to a combination of male and female fertility issues, or unknown causes. In many of these cases, causes of infertility are treatable. Nutritional and lifestyle changes should be the first step to increasing chances for conception. Smoking and caffeine, drug and alcohol consumption. environmental toxicants, and stress are related to infertility in men and women. Reproductive organs are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. A balanced, nutritional diet, and nutritional supplements with high antioxidant content can help reverse some of that damage. In women, hormone balance is critical to monthly ovulation and development of the corpus luteum (an ovarian follicle that release progesterone after release of the egg to prepare the uterus for implantation).
  • These and further and other objects and features of the invention are apparent in the disclosure, which includes the above ongoing written specification with the claims.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The invention provides combinations of beneficial bioeffecting compounds for promoting fertility in women. The invention provides a scientifically validated herbal/nutritional blend for women to improve infertility by helping to regulate the menstrual cycle and correct hormone imbalance (corpus luteum insufficiency) without increased chances of multiple births associated with drug therapy. The combination of amino acids, herbs, vitamins and minerals improves overall health and helps with many of the deficiencies that decrease fertility.
  • The herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B 12, iron, zinc and magnesium help promote womens' fertility.
  • The invention provides combinations of beneficial bioeffecting compounds for promoting fertility in men. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motilitv. The amino acid. L-camitine, promotes formation of healthy sperm.
  • The invention provides synergistic action of the combinations.
  • The two dietary supplements in male and female formulas are useful for men and women. Preferably, the distinct combinations are taken by both members of a couple in which the female age is between 21 and 46. The distinct combinations are useful for couples who have tried for 6 months or more, up to three years, to become pregnant without success. Preferably, patients take 2-4 capsules per day of the distinct formulas for three months. In women it is useful to record their basal temperature daily using thermometers and charts and to have their blood drawn for progesterone analysis at day 18-22 of the first menstrual cycle prior to taking the supplement. For men, it is useful to submit a sperm sample at the same time for analysis of count and motility. Prior to submitting sperm samples, 2-4 days abstinence is suggested for best results. No fevers over 101 degrees in the three months prior to taking the new combinations should be encountered. It is useful to repeat the analyses during the fourth menstrual cycle of the study. The first month is needed to develop baselines, followed by three months of taking the combinations product or placebo.
  • Preferred ranges of the combinations considered in percent by weight are: Components Minimum % Maximum % Women's formula Vitex (chasteberry) 2 10 L-arginine 40 60 Green tea 5 20 Vitamin E 5 20 Selenium .01 1 Vitamins B6, B12 .01 1 Folic acid .01 1 Iron .1 5 Magnesium 10 40 Zinc .1 5
  • Men's Formula Components Minimum % Maximum % L-carnitine 40 70 Ferulic acid in Dong Quai .1 10 Vitamins C and E 10 30 Coenzyme coQ10 .1 5 Selenium .01 1 Zinc .1 10 B vitamins .001 1
  • Acceptable ranges of womens' and mens' formulations are: Women's Formula Components Minimum % Maximum % Vitex (chasteberry) 1 20 L-arginine 20 70 Green tea 0 30 Vitamin E 0 30 Selenium 0 2 Vitamins B6, B12 0 2 Folic acid 0 2 Iron 0 7 Magnesium 5 50 Zinc .01 10
  • Men's Formula Components Minimum % Maximum % L-carnitine 20 80 Ferulic acid in Dong Quai 0 20 Vitamins C and E .01 40 Coenzyme coQ10 .01 10 Selenium 0 3 Zinc .01 15 B vitamins 0 5
  • Examples of useful formulation in percent by weight are: Women's formula Components Vitex (chasteberry) 5 L-arginine 50 Green tea 11 Vitamin E 11 Selenium .03 Vitamins B6, B12 .03 Folic acid .03 Iron 1 Magnesium 20 Zinc 1 100%
  • Men's Formula Components L-carnitine 60 Ferulic acid in Done Quai 6 Vitamins C and E 25 Coenzyme coQ10 3 Selenium 6 Zinc 5 B Vitamins 4 100%
  • While the invention has been described with references to specific embodiments, modifications and variations of the invention may be constructed without departing from the scope of the invention, which is defined in the following ciaims.

Claims (46)

1-9. (canceled)
10. A supplement, comprising a herb, Vitex agnus-castus (chasteberry) for enhancing hormone balance, increasing progesterone release and ovulation frequency, antioxidants, green tea, vitamin E, and selenium for improving reproductive fertility, L-arginine, an amino acid for stimulating reproductive organs by improving circulation, folic acid, vitamins B6 and B12, iron, zinc and magnesium for promoting women's fertility.
11. A method of promoting fertility health in women comprising taking a dietary supplement of L-arginine, magnesium, green tea, vitamin E, Vitex agnus-castus, iron, zinc, selenium, vitamins B6 and B12 and folic acid.
12. The method of claim 11, wherein the dietary supplement further comprises the following components in percentages by weight: about 50% L-arginine, about 20% magnesium, about 5% green tea, about 11% vitamin E, about 5% Vitex, about 1% iron, about 1% zinc and less than about 1% of each selenium, vitamins B6 and B12 and folic acid.
13. The method of claim 11, wherein the components are present in the proportion in parts by weight of about 10 to 80% L-arginine, an amino acid, about 5 to 50% magnesium, about 5 to 50% antioxidants, including green tea, vitamin E or selenium, 2 to 20% Vitex agnus-castus (chasteberry), about 0.1 to 10% iron, about 0.1 to 10% zinc, about 0.001 to 1% folic acid, about 0.001 to 1% vitamins B6 and B12.
14. The method of claim 11, wherein the components are present in the proportion in parts by weight of about 40 to 80% L-arginine, an amino acid, about 20 to 50% antioxidants, including green tea, vitamin E or selenium, about 20 to 50% magnesium, about 4 to 20% Vitex agnus-castus (chasteberry), about 1 to 10% iron, about 1 to 10 % zinc, about 0.01 to 1% folic acid, and about 0.3 to 1% vitamins B6 and B12.
15. A method for promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in effective amounts of the following components present in proportions in parts by weights of about 10 to 80% L-arginine, an amino acid, about 5 to 50% magnesium, about 5 to 50% antioxidants, including green tea, vitamin E or selenium, 2 to 20% Vitex agnus-castus (chasteberry), about 0.1 to 10% iron, about 0.1 to 10% zinc, about 0.001 to 1% folic acid, about 0.001 to 1% vitamins B6 and B12.
16. A method for promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in effective amounts of the following components present in proportions in parts by weights of about 40 to 80% L-arginine, an amino acid, about 20 to 50% antioxidants, including green tea, vitamin E or selenium, about 20 to 50% magnesium, about 4 to 20% Vitex agnus-castus (chasteberry), about 1 to 10% iron, about 1 to 10 % zinc, about 0.01 to 1% folic acid, and about 0.3 to 1% vitamins B6 and B12.
17. A method for promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in effective amounts of the following components present in proportions in parts by weights of about 10 to 80% L-arginine, an amino acid, about 10 to 50% magnesium, about 5 to 50% antioxidants, including green tea, vitamin E or selenium, about 1 to 20% Vitex agnus-castus (chasteberry), about 0.1 to 10% iron.
18. A method of promoting a women's fertility by taking a new supplement, comprising a herb, Vitex agnus-castus (chasteberry) for enhancing hormone balance, increasing progesterone release and ovulation frequency, antioxidants, green tea, vitamin E, and selenium for improving overall reproductive health, L-arginine, an amino acid for stimulating reproductive organs by improving circulation, folic acid, vitamins B6 and B12, iron, zinc and magnesium for promoting women's' fertility.
19. A supplement for promoting women's fertility comprising an herb for enhancing hormone balance, increasing progesterone release and ovulation frequency and an amino acid for stimulating reproductive organs by improving circulation.
20. The supplement of claim 19, wherein the herb is Vitex agnus-castus.
21. The supplement of claim 20, wherein the amino acid is L-arginine.
22. The supplement of claim 21, further comprising one or more antioxidants for improving reproductive fertility.
23. The supplement of claim 22, wherein the antioxidants are selected from the group consisting of green tea, vitamin E, selenium, and combinations thereof.
24. The supplement of claim 22, further comprising folic acid.
25. The supplement of claim 24, further comprising vitamins B6 and B12.
26. The supplement of claim 25, further comprising iron, zinc and magnesium.
27. A method of promoting fertility health in women comprising taking a dietary supplement comprising an herb for enhancing hormone balance, increasing progesterone release and ovulation frequency and an amino acid for stimulating reproductive organs by improving circulation.
28. The method of claim 27, wherein the taking a dietary supplement comprises taking the supplement comprising L-arginine and Vitex agnus-castus.
29. The method of claim 27, wherein the taking a dietary supplement comprises taking the supplement comprising one or more antioxidants.
30. The method of claim 29, wherein the antioxidants are selected from the group consisting of green tea, vitamin E, selenium, and combinations thereof.
31. The method of claim 29, wherein the taking a dietary supplement comprises taking the supplement comprising iron, magnesium, zinc, and combinations thereof.
32. The method of claim 31, wherein the taking the supplement comprises taking the supplement comprising vitamins B6 and B12.
33. The method of claim 32, wherein the taking the supplement comprises taking the supplement comprising folic acid.
34. The method of claim 33, wherein the dietary supplement further comprises the following components in percentages by weight: about 50% L-arginine, about 20% magnesium, about 5% green tea, about 11% vitamin E, about 5% Vitex, about 1% iron, about 1% zinc and less than about 1% of each of selenium, vitamins B6 and B12 and folic acid.
35. The method of claim 33, wherein the components are present in the proportion in parts by weight of about 10 to 80% L-arginine, an amino acid, about 5 to 50% magnesium, about 5 to 50% antioxidants, including green tea, vitamin E or selenium, 2 to 20% Vitex agnus-castus (chasteberry), about 0.1 to 10% iron, about 0.1 to 10% zinc, about 0.001 to 1% folic acid, about 0.001 to 1% vitamins B6 and B12.
36. The method of claim 33, wherein the components are present in the proportion in parts by weight of about 40 to 80% L-arginine, an amino acid, about 20 to 50% antioxidants, including green tea, vitamin E or selenium, about 20 to 50% magnesium, about 4 to 20% Vitex agnus-castus (chasteberry), about 1 to 10% iron, about 1 to 10 % zinc, about 0.01 to 1% folic acid, and about 0.3 to 1% vitamins B6 and B12.
37. A method for promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in effective amounts present in proportions in parts by weights of about 10 to 80% L-arginine and about 2 to 20% Vitex agnus-castus.
38. The method of claim 37, further comprising in combination components in effective amounts present in proportions in parts by weights of about 5 to 50% magnesium, about 5 to 50% antioxidants including green tea, vitamin E or selenium, about 0.1 to 10% iron, about 0.1 to 10% zinc, about 0.001 to 1% folic acid, about 0.001 to 1% vitamins B6 and B12.
39. A method for promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in effective amounts present in proportions in parts by weights of about 40 to 80% L-arginine and about 4 to 20% Vitex agnus-castus.
40. The method of claim 39, further comprising in combination components in effective amounts present in proportions in parts by weights of about 20 to 50% antioxidants, including green tea, vitamin E or selenium, about 20 to 50% magnesium, about 1 to 10% iron, about 1 to 10 % zinc, about 0.01 to 1% folic acid, and about 0.3 to 1% vitamins B6 and B12.
41. A method for promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in effective amounts present in proportions in parts by weights of about 10 to 80% L-arginine and about 1 to 20% Vitex agnus-castus.
42. The method of claim 41, further comprising in combination components in effective amounts present in proportions in parts by weights of about 10 to 50% magnesium, about 5 to 50% antioxidants including green tea, vitamin E or selenium, about 0.1 to 10% iron.
43. A method of promoting a women's fertility by taking a new supplement, comprising an herb Vitex agnus-castus (chasteberry) for enhancing hormone balance, increasing progesterone release and ovulation frequency, an amino acid L-arginine for stimulating reproductive organs by improving circulation, and antioxidants for improving overall reproductive health.
44. The method of claim 43, wherein the antioxidants are selected from the group consisting of green tea, vitamin E, selenium, and combinations thereof.
45. The method of claim 44, further comprising folic acid, vitamins B6 and B12, iron, zinc and magnesium for promoting women's fertility.
46. A supplement for improving fertility health comprising effective amounts of components of Vitex agnus-castus (chasteberry), green tea, and L-arginine for improving reproductive fertility, treating female infertility, enhancing hormone balance, stimulating reproductive organs, increasing progesterone release, increasing ovulation rate, and increasing pregnancy rate.
47. The supplement of claim 46, wherein the components are present in parts by weight of about 74% L-arginine, about 18.5% green tea, and about 7.4% Vitex agnus-castus (chasteberry).
48. The supplement of claim 46, wherein the components are present in parts by weight of about 10 to 80% L-arginine, about 5 to 50% green tea, and about 2 to 20% Vitex agnus-castus (chasteberry).
49. The supplement of claim 46, wherein the components are present in parts by weight of about 40 to 80% L-arginine, about 20 to 50% green tea, and about 4 to 20% Vitex agnus-castus (chasteberry).
50. A method for improving and promoting fertility health in women comprising taking a supplement having fertility promoting activity in females comprising in combination components in parts by weights of about 10 to 80% L-arginine, about 5 to 50% green tea, and about 2 to 20% Vitex agnus-castus (chasteberry) for improving reproductive fertility, treating female infertility, enhancing hormone balance, stimulating reproductive organs, increasing progesterone release, increasing ovulation rate, and increasing pregnancy rate.
51. A method of improving and promoting fertility health in women comprising taking a dietary supplement of effective amounts of components of L-arginine, green tea, and Vitex agnus-castus (chasteberry) for improving reproductive fertility, treating female infertility, enhancing hormone balance, stimulating reproductive organs, increasing progesterone release, increasing ovulation rate, and increasing pregnancy rate.
52. The method of claim 51, wherein the dietary supplement comprises the components in percentages by weight of about 74% L-arginine, about 18.5% green tea, and about 7.4% Vitex agnus-castus (chasteberry).
53. The method of claim 51, wherein the components are present in the parts by weight of about 10 to 80% L-arginine, about 5 to 50% green tea, and about 2 to 20% Vitex agnus-castus (chasteberry).
54. The method of claim 51,, wherein the components are present in parts by weight of about 40 to 80% L-arginine, abbut 20 to 50% green tea, and about 4 to 20% Vitex agnus-castus (chasteberry).
US11/214,927 2000-12-22 2005-08-31 Method and composition for improving fertility health in female and male animals and humans Abandoned US20050287228A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/742,412 US6497885B2 (en) 2000-12-22 2000-12-22 Method and composition for improving fertility health in female and male animals and humans
US10/252,698 US7045151B2 (en) 2000-12-22 2002-09-24 Method and composition for improving fertility health in female and male animals and humans
US11/214,927 US20050287228A1 (en) 2000-12-22 2005-08-31 Method and composition for improving fertility health in female and male animals and humans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/214,927 US20050287228A1 (en) 2000-12-22 2005-08-31 Method and composition for improving fertility health in female and male animals and humans

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/252,698 Division US7045151B2 (en) 2000-12-22 2002-09-24 Method and composition for improving fertility health in female and male animals and humans

Publications (1)

Publication Number Publication Date
US20050287228A1 true US20050287228A1 (en) 2005-12-29

Family

ID=24984736

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/742,412 Active US6497885B2 (en) 2000-12-22 2000-12-22 Method and composition for improving fertility health in female and male animals and humans
US10/252,698 Active 2021-02-01 US7045151B2 (en) 2000-12-22 2002-09-24 Method and composition for improving fertility health in female and male animals and humans
US11/214,927 Abandoned US20050287228A1 (en) 2000-12-22 2005-08-31 Method and composition for improving fertility health in female and male animals and humans

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/742,412 Active US6497885B2 (en) 2000-12-22 2000-12-22 Method and composition for improving fertility health in female and male animals and humans
US10/252,698 Active 2021-02-01 US7045151B2 (en) 2000-12-22 2002-09-24 Method and composition for improving fertility health in female and male animals and humans

Country Status (1)

Country Link
US (3) US6497885B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102141A1 (en) * 2006-10-30 2008-05-01 Maria Antoinette Brandes Use as a means to improve fertility of a phytotherapeutic composition and method for improving and/or promoting fertility health
AT503219B1 (en) * 2006-02-03 2008-07-15 Annerl Brigitte Combination preparation based on antioxidants to improve the seed quality
US20100159036A1 (en) * 2006-10-30 2010-06-24 Maria Antoinette Brandes Use as a means to improve fertility of a phytotherapeutic composition and method for improving and/or promoting fertility health
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
WO2006053217A1 (en) * 2004-11-12 2006-05-18 Mccleary, Edward Larry Weight loss composition and method
US20030059489A1 (en) * 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
WO2003037343A1 (en) * 2001-10-30 2003-05-08 Lonza Ag Composition comprising folic acid and carnitine useful to enhance male fertility
DE10304590A1 (en) * 2003-02-05 2005-01-27 Heinz Kiefer Use of a medicament comprising Agni casti fructus, Cimicifugae racemosae rhizoma and D-alpha-tocopherol for treating climacteric disorders involving impaired libido
US20040228931A1 (en) * 2003-05-12 2004-11-18 Pharmachem Laboratories, Inc. Novel composition for hormonal balance and uses thereof
AT354290T (en) * 2003-11-04 2007-03-15 Korfitsen Jens Peter Corfitz Preparation for a nutritional supplement
US7410657B2 (en) * 2004-09-30 2008-08-12 Ai Ja Lee Alternative remedy-based composition for enhancing fertility
US20060110478A1 (en) * 2004-11-22 2006-05-25 Mccleary Edward L Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction
WO2006057893A2 (en) * 2004-11-22 2006-06-01 Edward Larry Mccleary Composition, delivery system and method for promoting healthy sexual function
FR2884691B1 (en) * 2005-04-21 2007-07-20 Formquest Ltd Food supplement comprising a combination of antioxidant agents and energy agents useful as aid for fertility in man and in women
JP5088873B2 (en) * 2005-07-04 2012-12-05 国立大学法人 東京医科歯科大学 L-arginine-containing pharmaceutical composition and food and beverage composition
CA2642008A1 (en) * 2005-07-05 2007-01-11 Fertility Technologies Pty Ltd Methods and compositions for improving pregnancy outcome
CA2628313A1 (en) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
FR2893848B1 (en) * 2005-11-28 2011-11-11 Physcience Phytohormonal composition and its use as a hormonal substitute
ITBO20060544A1 (en) * 2006-07-21 2008-01-22 Angelo Chieregati Prepared for the treatment of infertility '
US10070680B2 (en) 2008-06-13 2018-09-11 Nike, Inc. Footwear having sensor system
US9549585B2 (en) 2008-06-13 2017-01-24 Nike, Inc. Footwear having sensor system
WO2009152456A2 (en) 2008-06-13 2009-12-17 Nike, Inc. Footwear having sensor system
US9002680B2 (en) * 2008-06-13 2015-04-07 Nike, Inc. Foot gestures for computer input and interface control
ES2333842B1 (en) * 2009-11-30 2011-02-10 Laboratorios Q Pharma S.L. PHARMACEUTICAL COMPOSITION INTENDED TO IMPROVE THE QUALITY OF THE Sperm.
JP5868848B2 (en) * 2010-05-21 2016-02-24 株式会社カネカ Pig feed and its feeding method
FR2964834B1 (en) * 2010-09-21 2012-09-28 Marc Cohen Anti-oxidizing composition for preventing infertility in man
JP5847831B2 (en) 2010-11-10 2016-01-27 ナイキ イノベイト シーブイ System and method for measuring and displaying athletic activity on a time basis
JP5782529B2 (en) 2011-02-17 2015-09-24 ナイキ イノベイト シーブイ Selection of physical activity data and association with image data
KR101754997B1 (en) 2011-02-17 2017-07-06 나이키 이노베이트 씨.브이. Footwear having sensor system
US9381420B2 (en) 2011-02-17 2016-07-05 Nike, Inc. Workout user experience
CN107411215A (en) 2011-02-17 2017-12-01 耐克创新有限合伙公司 The footwear of belt sensor system
US20130213147A1 (en) 2012-02-22 2013-08-22 Nike, Inc. Footwear Having Sensor System
US20130213146A1 (en) 2012-02-22 2013-08-22 Nike, Inc. Footwear Having Sensor System
US20190045877A9 (en) 2012-02-22 2019-02-14 Nike, Inc. Motorized Shoe With Gesture Control
DE102012217387A1 (en) * 2012-09-26 2014-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic use of hydrogen molecules
US9775874B1 (en) 2012-09-28 2017-10-03 The Daily Wellness Company Method for treating symptoms of hormone imbalance
US9743861B2 (en) 2013-02-01 2017-08-29 Nike, Inc. System and method for analyzing athletic activity
US9279734B2 (en) 2013-03-15 2016-03-08 Nike, Inc. System and method for analyzing athletic activity
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US400276A (en) * 1889-03-26 Grip-pulley wheel
US4321262A (en) * 1976-12-29 1982-03-23 Burnett Harvey L Medicament for arthritic conditions
US6242012B1 (en) * 1999-10-19 2001-06-05 Thomas Newmark Herbal composition for promoting hormonal balance in women and methods of using same
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6368640B1 (en) * 1998-04-03 2002-04-09 The Daily Wellness Company Method and composition for improving sexual fitness
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878124A (en) * 1956-03-10 1959-03-17 Bayer Ag Food additives
US3015567A (en) * 1959-03-20 1962-01-02 Du Pont Process for enriching the l-lysine content of food and the resulting product
US3360374A (en) * 1965-07-27 1967-12-26 Courtland Lab Process for making a dietary food product
JPS5133633B2 (en) 1973-08-31 1976-09-21
US3970750A (en) 1974-10-08 1976-07-20 Sandoz, Inc. Effervescent potassium chloride composition
US4168307A (en) * 1974-11-08 1979-09-18 Mitsubishi Chemical Industries Limited N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
ZA7703318B (en) 1976-06-18 1978-04-26 I Kleinberg Means and method for improving natural defenses against caries
US4340592A (en) 1980-03-14 1982-07-20 Adibi Siamak A Nutrient compositions and method of administering the same
JPS575692A (en) 1980-06-13 1982-01-12 Ajinomoto Co Inc Production of l-arginine through fermentation process
IT1133026B (en) 1980-06-30 1986-07-09 Manetti & Roberts Italo Brit Medicament base of d, l-l-arginine Pyroglutamate with attivita 'to nica in neuro-endocrine
JPS6345370B2 (en) 1980-12-03 1988-09-09 Ajinomoto Kk
JPS5855418A (en) 1981-09-25 1983-04-01 Akira Endo Remedy for hyperlipemia
CH655005A5 (en) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Pharmaceutical composition with metabolic and energy action usable in cardiac and vascular therapy.
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US5034377A (en) 1984-11-19 1991-07-23 Montefiore Hospital Association Of Western Pennsylvania Aqueous nutrient compositions comprising oligopeptides
GB8603171D0 (en) * 1986-02-08 1986-03-12 Howard A N Dietary product
US5248688A (en) * 1986-09-10 1993-09-28 Dudrick Medical Research Fund I, Ltd. Method and substrate composition for treating atherosclerosis
US5032608A (en) 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5041429A (en) * 1988-06-01 1991-08-20 Sanwa Kagaku Kenkyusho Co., Ltd. Cell activators, circulatory ameliorators and edible compositions
EP0347890B1 (en) * 1988-06-22 1993-03-17 Roussel Morishita Co., Ltd. Amino acid nutrient compositions
US4954526A (en) 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5380945A (en) * 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
US5464644A (en) 1989-09-27 1995-11-07 Kellogg Company Ready-to-eat-cereal containing psyllium and use thereof for lowering cholesterol levels
US5157022A (en) 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
JP2960947B2 (en) 1989-12-25 1999-10-12 日清製粉株式会社 Lipolytic enzyme inhibitors
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
DE69122099T2 (en) 1990-05-16 1997-04-17 Zbigniew Walaszek Composition and method for the prevention and treatment of hypercholesterinemia and cell proliferation disorders
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5106836A (en) 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5385937A (en) 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
FR2675692B1 (en) 1991-04-24 1995-01-13 Oreal
CA2066951A1 (en) 1991-04-26 1992-10-27 Kou Moriyama Edible composition
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
JP2702322B2 (en) * 1991-08-08 1998-01-21 フジックス株式会社 Active amino acid calcium, beverage containing the same, and method for producing the same
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
JPH05163139A (en) 1991-12-12 1993-06-29 Ajinomoto Co Inc Antiarteriosclerotic agent
US5262435A (en) * 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
WO1993018156A1 (en) 1992-03-05 1993-09-16 The General Hospital Corporation Endothelial nitric oxide synthase
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
GB9214247D0 (en) 1992-07-04 1992-08-19 Stephan Peter M Composition for use as a food or food supplement
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5439938A (en) 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
JPH06321786A (en) 1993-05-12 1994-11-22 Sekisui Chem Co Ltd Agent for inhibiting absorption of bile acid in enteric canal
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5428070A (en) 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5861168A (en) 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5852058A (en) 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
ZA9410015B (en) 1993-09-15 1995-11-08 William Henry Davis A pharmaceutical composition
JP3398449B2 (en) 1993-12-10 2003-04-21 常春 黒木 Cattle sexing method
US5500266A (en) 1994-03-10 1996-03-19 Eastman Kodak Company Spin-coating compensation for an optical storage medium with a substrate groove profile gradient
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
US5576287A (en) 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US5631031A (en) 1994-06-13 1997-05-20 Meade; Thomas L. Water-insoluble amino acid salt
US5543430A (en) 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5594032A (en) 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5523087A (en) 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5730987A (en) 1996-06-10 1998-03-24 Omar; Lotfy Ismail Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
US5883086A (en) * 1997-05-02 1999-03-16 Craft; John C. DHEA-containing nutritional supplement
JP3926888B2 (en) * 1997-05-27 2007-06-06 株式会社カネカ Cholesterol lowering agent
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US400276A (en) * 1889-03-26 Grip-pulley wheel
US4321262A (en) * 1976-12-29 1982-03-23 Burnett Harvey L Medicament for arthritic conditions
US6368640B1 (en) * 1998-04-03 2002-04-09 The Daily Wellness Company Method and composition for improving sexual fitness
US6544563B2 (en) * 1998-04-03 2003-04-08 The Daily Wellness Company Method and composition for improving sexual fitness
US6242012B1 (en) * 1999-10-19 2001-06-05 Thomas Newmark Herbal composition for promoting hormonal balance in women and methods of using same
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263667B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8197854B2 (en) 2005-08-04 2012-06-12 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
AT503219B1 (en) * 2006-02-03 2008-07-15 Annerl Brigitte Combination preparation based on antioxidants to improve the seed quality
US20080102141A1 (en) * 2006-10-30 2008-05-01 Maria Antoinette Brandes Use as a means to improve fertility of a phytotherapeutic composition and method for improving and/or promoting fertility health
US20100159036A1 (en) * 2006-10-30 2010-06-24 Maria Antoinette Brandes Use as a means to improve fertility of a phytotherapeutic composition and method for improving and/or promoting fertility health

Also Published As

Publication number Publication date
US20030026851A1 (en) 2003-02-06
US20020122834A1 (en) 2002-09-05
US7045151B2 (en) 2006-05-16
US6497885B2 (en) 2002-12-24

Similar Documents

Publication Publication Date Title
Mora-Esteves et al. Nutrient supplementation: improving male fertility fourfold
Lynn et al. Effects of pomegranate juice supplementation on pulse wave velocity and blood pressure in healthy young and middle-aged men and women
Belmaker et al. Human platelet monoamine oxidase changes during the menstrual cycle
Ensiyeh et al. Comparing ginger and vitamin B6 for the treatment of nausea and vomiting in pregnancy: a randomised controlled trial
Todini et al. Plasma total T3 and T4 concentrations in goats at different physiological stages, as affected by the energy intake
ES2283103T3 (en) Composition that teanina understands.
Al-Qarawi et al. Gastrointestinal transit in mice treated with various extracts of date (Phoenix dactylifera L.)
Shukla et al. Mucuna pruriens improves male fertility by its action on the hypothalamus–pituitary–gonadal axis
Hickey et al. Treatment of menopausal symptoms: what shall we do now?
US6200594B1 (en) Breast-enhancing, herbal compositions and methods of using same
Braga et al. Food intake and social habits in male patients and its relationship to intracytoplasmic sperm injection outcomes
JP2018012722A (en) Composition, method, and kit for regulating energy metabolism
Ahmad et al. Withania somnifera improves semen quality by regulating reproductive hormone levels and oxidative stress in seminal plasma of infertile males
Ahmad et al. Effect of Mucuna pruriens on semen profile and biochemical parameters in seminal plasma of infertile men
Fitzpatrick Reprint of Soy isoflavones: hope or hype?
US7229649B2 (en) Method and composition for improving sexual fitness
US8491943B2 (en) Method and composition for improved anabolism
Chandra Graying of the immune system: can nutrient supplements improve immunity in the elderly?
Westphal et al. A nutritional supplement for improving fertility in women
US6399116B1 (en) Rhodiola and used thereof
AU2009100215B4 (en) Methods and compositions for improving pregnancy outcome
JP5013673B2 (en) Orally administrable composition for improving hair and coat quality
US20120020982A1 (en) Formulations and treatments for trichology
Capasso et al. Silymarin BIO-C®, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats
McKay et al. The effects of a multivitamin/mineral supplement on micronutrient status, antioxidant capacity and cytokine production in healthy older adults consuming a fortified diet

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION